Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis (Q81091752)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

3

Hannu Kautiainen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Karin Laas

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Ritva Peltomaa

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Marjatta Leirisalo-Repo

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

15 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

published in

Clinical Rheumatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

927-932

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414967%20AND%20SRC:MED&resulttype=core&format=json

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

5 January 2020

cites work

1 reference

12 December 2020

Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept

1 reference

12 December 2020

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

12 December 2020

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

12 December 2020

Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?

1 reference

12 December 2020

[Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab]

1 reference

12 December 2020

The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis

1 reference

12 December 2020

Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria

1 reference

12 December 2020

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

1 reference

12 December 2020

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

1 reference

12 December 2020

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis

1 reference

12 December 2020

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

1 reference

12 December 2020

Joint impairment is strongly correlated with disability measured by self-report questionnaires. Functional status assessment of individuals with rheumatoid arthritis in a population based series.

1 reference

12 December 2020

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

1 reference

12 December 2020

Preliminary criteria for clinical remission in rheumatoid arthritis

1 reference

12 December 2020

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

1 reference

12 December 2020

Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis.

1 reference

12 December 2020

Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept

1 reference

12 December 2020

Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

1 reference

12 December 2020

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

1 reference

12 December 2020

Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

1 reference

12 December 2020

10.1007/S10067-008-0880-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference